Novel Oral Drug Obefazimod Sustains Ulcerative Colitis Remission in Over 52% of Patients for Two Years

Novel Oral Drug Obefazimod Sustains Ulcerative Colitis Remission in Over 52% of Patients for Two Years | OpenHealth